The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Put Hughes Syndrome on Your Radar

Put Hughes Syndrome on Your Radar

April 1, 2007 • By Graham R.V. Hughes, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

There are two “new” diseases of the late 20th century—AIDS and the antiphospholipid syndrome.
—Miguel Villardel, MD, professor of medicine, Hospital Valle de Hebron, Barcelona

You Might Also Like
  • Why Antiphospholipid Antibody Syndrome Should Be On Your Radar
  • APS: What Rheumatologists Should Know about Hughes Syndrome
  • Antiphospholipid Syndrome
Explore This Issue
April 2007

Since its clinical description in 1983, antiphospholipid syndrome (APS or Hughes Syndrome) has become the domain not only of rheumatologists and obstetricians, but of neurologists, cardiologists, psychiatrists, otolaryngologists, and orthopedists. Like lupus, APS embraces all clinical specialities.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Brief History of APS

In 1983, my colleagues and I described in detail a syndrome involving—uniquely—both arterial and venous thrombosis, and including prominent neurological features, including strokes, seizures, memory loss, and chorea. In addition, this syndrome was associated with occasional thrombocytopenia, livedo reticularis, labile hypertension, recurrent miscarriage, and internal organ thrombosis such as Budd-Chiari syndrome.1,2 We recognized that the syndrome was “sufficiently different from typical systemic lupus to warrant separate consideration”—originally calling it the anticardiolipin syndrome.2 Led by the late Aziz Gharavi, MD, and E. Nigel Harris, MPhil, MD, DM, we set up sensitive immunoassays for antiphospholipid antibodies (aPL), changed the name to APS, and introduced the term primary APS for stand-alone cases.2,3

The worldwide interest in this syndrome has led to its recognition in a wide variety of clinical states increasing diagnosis. Indeed, it seems a fairly safe prediction that APS will overtake lupus in prevalence. A rough one-in-five rule seems to apply for the contribution of APS to various clinical conditions—one in five cases of recurrent miscarriage, one in five strokes in people under 45, one in five cases of deep vein thrombosis (DVT). Eventually, this estimate may also pertain to other major illnesses including myocardial infarction in the young, idiopathic teenage epilepsy, and possibly even migraine.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pathogenesis and Clinical Features

APS is an autoimmune disease in which antibodies directed against phospholipid-protein complexes appear to lead directly to thrombosis. Like all autoimmune diseases APS has a genetic component, and cases of thyroid disease, Sjögren’s syndrome, and lupus are frequently seen in families with APS.

While arterial and venous thromboses are the hallmarks of the syndrome, there are other clinical clues. Headache—particularly migraine—is often an early feature going back to childhood, and often familial. Livedo reticularis is an important physical sign, and a dry Shirmer’s test, suggesting underlying Sjögren’s syndrome, is a clue to the disease’s autoimmune pedigree. Table 1 lists some of the major differences between APS and other pro-thrombotic disorders.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
Clinical Pointers in the Differential Diagnosis of APS
click for large version
Table 1: Clinical Pointers in the Differential Diagnosis of APS

Neurological Considerations

Stroke: The most feared complication of APS is stroke, with up to 20% of strokes in people under 45 possibly having this etiology. In this setting, the MRI can be misleading (e.g., false negatives) and we look forward to the development of more sensitive and available screening techniques. Estimates for the frequency of stroke in patients with APS vary widely, and some studies have been hampered by methodological problems.4

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Conditions Tagged With: antiphospholipid, Autoimmune, Hughes Syndrome, Pathogenesis, TreatmentIssue: April 2007

You Might Also Like:
  • Why Antiphospholipid Antibody Syndrome Should Be On Your Radar
  • APS: What Rheumatologists Should Know about Hughes Syndrome
  • Antiphospholipid Syndrome
  • Advancements in Diagnosis, Treatment for Antiphospholipid Syndrome

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.